Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
2024年5月1日 - 5:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, will hold its first quarter earnings
conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s
quarterly earnings will be released the same day after the market
closes.
During the call, Myriad management will provide a
financial overview and business update of the company’s performance
for the first quarter 2024.
A live webcast of the earnings conference call can
be accessed on Myriad’s Investor Relations website at
investor.myriad.com. To participate in the live conference call via
telephone, please register here. Upon registering, a dial-in number
and unique PIN will be provided to join the conference call. An
archived webcast of the call will be available at
investor.myriad.com following the call.
Q2 Investor ConferencesManagement
will also be participating in the following investor
conferences:
- The Bank of America Securities Health Care Conference with a
presentation from Sam Raha, chief operating officer, and Scott
Leffler, chief financial officer, on Tuesday, May 14, 2024 at
8:15pm ET.
- The Piper Sandler Virtual Cancer Testing Day with a
presentation from Dale Muzzey, chief scientific officer, on May 21,
2024 at 11am ET.
- The Leerlink Partners Healthcare Crossroads Conference with a
presentation from Paul J. Diaz, president and CEO, and Scott
Leffler, chief financial officer, on May 30, 2024 at 11am ET.
- The 45th Annual Global Goldman Sachs Global Healthcare
Conference with a presentation from Paul J. Diaz, president and
CEO, and Scott Leffler, chief financial officer, on June 12, 2024
at 3:20pm ET.
Live and archived webcasts of all presentations can
be viewed at investor.myriad.com.
About Myriad GeneticsMyriad
Genetics is a leading genetic testing and precision medicine
company dedicated to advancing health and well-being for all.
Myriad develops and offers genetic tests that help assess the risk
of developing disease or disease progression and guide treatment
decisions across medical specialties where genetic insights can
significantly improve patient care and lower healthcare costs. For
more information, visit www.myriad.com.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 5 2024 まで 6 2024
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 6 2023 まで 6 2024